PF614-MPAR (Combined TAAP™/MPAR® Oxycodone)
Management of severe chronic pain with overdose protection
Phase 2Active (PF614-MPAR-102 Study Part 2 fully enrolled)
Key Facts
Indication
Management of severe chronic pain with overdose protection
Phase
Phase 2
Status
Active (PF614-MPAR-102 Study Part 2 fully enrolled)
Company
About Ensysce Biosciences
Ensysce Biosciences is pioneering a chemistry-first approach to prevent prescription drug abuse and overdose through its two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). The company's lead programs have received significant FDA designations, including Fast Track and Breakthrough Therapy, and it has secured approximately $12 million in non-dilutive grant funding from the National Institute on Drug Abuse. Ensysce is advancing its clinical pipeline with a focus on creating safer pain management therapies that could revolutionize the standard of care in a market with high unmet need.
View full company profile